Boston Sci acquires two devices to treat CTOs

Kaitlyn Dmyterko | | Health Imaging | Enterprise Imaging
Boston Scientific has acquired a re-entry catheter and intraluminal chronic total occlusion (CTO) crossing device from S.I. Therapies and ReVascular Therapeutics that will help treat complex peripheral lesions.

The Natick, Mass.-based company said it acquired the re-entry catheter from Israel-based S.I. Therapies back in November 2010 and that the deal with Sunnyvale, Calif.-based ReVascular Therapeutics is expected to close this month. Additionally, Boston Scientific said that the products are expected to be launched globally in approved markets later this year.

While the financial details of the deals were not disclosed, Boston Scientific said that both transactions are expected to have an impact on adjusted earnings in 2011 and 2012 and be accretive thereafter.

Kaitlyn Dmyterko

Related Content

Less than half of incidental interstitial lung abnormalities on CT exams are reported
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Rads are more accurate when they have access to patients' self-reported symptoms
AI-based software improves follow-up imaging adherence by 74%

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.